World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
94
Citations
35469
World Ranking
10413
National Ranking
5364

Howard A. Fine publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Howard A. Fine sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 282 publications — 13th percentile

13% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Howard A. Fine D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Howard A. Fine sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 94 D-Index — 49th percentile

49% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Research.com Recognitions

  • 2017 - National Institutes of Health Director's Pioneer Award

Overview

Howard A. Fine is affiliated with Cornell University in the United States and specializes in medical research with a focus on genetics and molecular biology. Their work prominently addresses cancer research, particularly related to glioma diagnosis and treatment.

The areas of study relevant to Fine's research include:

  • Medicine
  • Biochemistry, Genetics and Molecular Biology

Fine's subfields of study encompass genetics, molecular biology, cancer research, pulmonary and respiratory medicine, and radiology, nuclear medicine, and imaging.

  • Genetics
  • Molecular Biology
  • Cancer Research
  • Pulmonary and Respiratory Medicine
  • Radiology, Nuclear Medicine and Imaging

Their research addresses various specific topics, including glioma diagnosis and treatment, brain metastases and treatment, cancer hypoxia and metabolism, management of meningioma and schwannoma, cancer cells and metastasis, immune cells in cancer, and single-cell and spatial transcriptomics.

  • Glioma Diagnosis and Treatment
  • Brain Metastases and Treatment
  • Cancer, Hypoxia, and Metabolism
  • Meningioma and schwannoma management
  • Cancer Cells and Metastasis
  • Immune cells in cancer
  • Single-cell and spatial transcriptomics

Frequent publication venues for Fine's work include Neuro-Oncology, Cancer Discovery, Cancer Cell, World Neurosurgery, and bioRxiv (Cold Spring Harbor Laboratory).

  • Neuro-Oncology
  • Cancer Discovery
  • Cancer Cell
  • World Neurosurgery
  • bioRxiv (Cold Spring Harbor Laboratory)

Collaborators regularly working with Fine include Rajiv Magge, Rohan Ramakrishna, Stéfano M. Cirigliano, Theodore H. Schwartz, and David J. Pisapia.

  • Rajiv Magge
  • Rohan Ramakrishna
  • Stéfano M. Cirigliano
  • Theodore H. Schwartz
  • David J. Pisapia

Recent publications by Fine feature research in cancer biology and therapeutic approaches, notably:

  • Diffuse Glioma Heterogeneity and Its Therapeutic Implications, 2021, Cancer Discovery
  • Pluripotent stem cell-derived epithelium misidentified as brain microvascular endothelium requires ETS factors to acquire vascular fate, 2021, Proceedings of the National Academy of Sciences
  • Tumor Microenvironment Is Critical for the Maintenance of Cellular States Found in Primary Glioblastomas, 2020, Cancer Discovery
  • Tissue factor is a critical regulator of radiation therapy-induced glioblastoma remodeling, 2023, Cancer Cell
  • Microenvironment-Driven Dynamic Chromatin Changes in Glioblastoma Recapitulate Early Neural Development at Single-Cell Resolution, 2023, Cancer Research

Howard A. Fine has been recognized with the National Institutes of Health Director's Pioneer Award in 2017.

Best Publications

  • Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines.

    Jeongwu Lee;Svetlana Kotliarova;Yuri Kotliarov;Aiguo Li

  • Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma

    Teri N. Kreisl;Lyndon Kim;Kraig Moore;Paul Duic

  • Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain

    Lixin Sun;Ai Min Hui;Qin Su;Alexander Vortmeyer

  • microRNA-7 Inhibits the Epidermal Growth Factor Receptor and the Akt Pathway and Is Down-regulated in Glioblastoma

    Benjamin Kefas;Jakub Godlewski;Laurey Comeau;Yunqing Li

  • SSEA-1 Is an Enrichment Marker for Tumor-Initiating Cells in Human Glioblastoma

    Myung Jin Son;Kevin D Woolard;Do Hyun Nam;Jeongwu Lee

  • Expression of Notch-1 and its ligands, Delta-like-1 and Jagged-1, is critical for glioma cell survival and proliferation.

    Benjamin W. Purow;Raqeeb M. Haque;Martha W. Noel;Qin Su

  • Stereotactic Radiosurgery for the Definitive, Noninvasive Treatment of Brain Metastases

    Eben Alexander;Thomas M. Moriarty;Roger B. Davis;Patrick Y. Wen

  • Cellular-Telephone Use and Brain Tumors

    Peter D. Inskip;Robert E. Tarone;Elizabeth E. Hatch;Timothy C. Wilcosky

  • Phase II Trial of the Antiangiogenic Agent Thalidomide in Patients With Recurrent High-Grade Gliomas

    Howard A. Fine;William D. Figg;Kurt Jaeckle;Patrick Y. Wen

  • Phase III Study of Enzastaurin Compared With Lomustine in the Treatment of Recurrent Intracranial Glioblastoma

    Wolfgang Wick;Vinay K. Puduvalli;Marc C. Chamberlain;Martin J. van den Bent

  • Primary Central Nervous System Lymphoma

    Howard A. Fine;Robert J. Mayer

  • Epigenetic-mediated dysfunction of the bone morphogenetic protein pathway inhibits differentiation of glioblastoma-initiating cells.

    Jeongwu Lee;Myung Jin Son;Kevin D Woolard;Nicholas M. Donin

  • Modeling Patient-Derived Glioblastoma with Cerebral Organoids.

    Amanda Linkous;Demosthenes Balamatsias;Matija Snuderl;Lincoln Edwards

  • Phase I/II Study of Imatinib Mesylate for Recurrent Malignant Gliomas: North American Brain Tumor Consortium Study 99-08

    Patrick Y. Wen;W. K Alfred Yung;Kathleen R. Lamborn;Patricia L. Dahia

  • Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas.

    Kathleen R. Lamborn;W. K.Alfred Yung;Susan M. Chang;Patrick Y. Wen

  • Rembrandt: helping personalized medicine become a reality through integrative translational research.

    Subha Madhavan;Jean Claude Zenklusen;Yuri Kotliarov;Himanso Sahni

  • The treatment of recurrent brain metastases with stereotactic radiosurgery.

    Jay S. Loeffler;Hanne M. Kooy;Patrick Y. Wen;Howard A. Fine

  • Scale to Predict Survival After Surgery for Recurrent Glioblastoma Multiforme

    John K. Park;Tiffany Hodges;Leopold Arko;Michael Shen

  • A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy

    Jeffrey J. Raizer;Lauren E. Abrey;Andrew B. Lassman;Susan M. Chang

  • Comparison of stereotactic radiosurgery and brachytherapy in the treatment of recurrent glioblastoma multiforme

    Dennis C. Shrieve;Eben Alexander;Patrick Y. Wen;Howard A. Fine

Frequent Co-Authors

Patrick Y. Wen
Patrick Y. Wen Harvard University
Peter McL. Black
Peter McL. Black University of British Columbia
Jay S. Loeffler
Jay S. Loeffler Harvard University
Michael D. Prados
Michael D. Prados University of California, San Francisco
Martha S. Linet
Martha S. Linet National Institutes of Health
W. K. Alfred Yung
W. K. Alfred Yung The University of Texas MD Anderson Cancer Center
Timothy F. Cloughesy
Timothy F. Cloughesy University of California, Los Angeles
Jeongwu Lee
Jeongwu Lee Case Western Reserve University
Minesh P. Mehta
Minesh P. Mehta University of Maryland, Baltimore
Susan M. Chang
Susan M. Chang University of California, San Francisco

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in a medical career but seeking flexible study options, there are a variety of online degree pathways to consider. Many entry-level medical roles, such as medical billing and coding, can be launched by earning a certification online. It’s important to consider the medical billing and coding certification cost, as this can vary widely depending on the program chosen.

Nursing is another popular field for online study. Prospective nurse practitioners can reduce expenses by exploring the cheapest online np programs, making advanced nursing roles more accessible. Registered nurses seeking to advance their credentials might want to look for the cheapest rn to bsn online programs, which offer a convenient way to move forward in their careers.

For those interested in leadership or research roles, there are also affordable phd nursing programs available online. With careful research and planning, students can find highly respected programs that offer flexibility, affordability, and strong career outcomes.

Best Scientists Citing Howard A. Fine

Trending Scientists

Recently Published Articles